Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A van Elsas

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
The Journal of Experimental Medicine|August 3, 1999
Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentationA van Elsas, A A Hurwitz, J P Allison
Current Opinion in Immunology|September 28, 2000
Costimulatory wars: the tumor menaceA A Hurwitz, E D Kwon, A van Elsas
Clinical and Experimental Immunology|November 6, 2020
Isotype selection for antibody-based cancer therapyN Vukovic, A van Elsas, J S Verbeek, et al.
British Journal of Cancer|March 10, 1999
p53 mutations in human cutaneous melanoma correlate with sun exposure but are not always involved in melanomagenesisS F Zerp, A van Elsas, L T Peltenburg, et al.
The Journal of Investigative Dermatology|November 1, 1994
ras oncogene activation does not induce sensitivity to natural killer cell-mediated lysis in human melanomaA van Elsas, E van Deursen, R Wielders, et al.
Melanoma Research|August 1, 1997
UV-induced N-ras mutations are T-cell targets in human melanomaA van Elsas, C Scheibenbogen, C van der Minne, et al.
Cancer Research|February 1, 1997
Activated N-ras contributes to the chemoresistance of human melanoma in severe combined immunodeficiency (SCID) mice by blocking apoptosisB Jansen, H Schlagbauer-Wadl, H G Eichler, et al.
Systems Biology|September 22, 2006
Systems biology for battling rheumatoid arthritis: application of the Entelos PhysioLab platformJ A C Rullmann, H Struemper, N A Defranoux, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 1, 1995
Analysis of N-ras mutations in human cutaneous melanoma: tumor heterogeneity detected by polymerase chain reaction/single-stranded conformation polymorphism analysisA van Elsas, S Zerp, S van der Flier, et al.
International Journal of Cancer|September 17, 1996
N-ras oncogene expression changes the growth characteristics of human melanoma in two independent SCID-hu mouse modelsB Jansen, S A Inoue, H Wadl, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
The Journal of Experimental Medicine|August 3, 1999
Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentationA van Elsas, A A Hurwitz, J P Allison
Current Opinion in Immunology|September 28, 2000
Costimulatory wars: the tumor menaceA A Hurwitz, E D Kwon, A van Elsas
Clinical and Experimental Immunology|November 6, 2020
Isotype selection for antibody-based cancer therapyN Vukovic, A van Elsas, J S Verbeek, et al.
British Journal of Cancer|March 10, 1999
p53 mutations in human cutaneous melanoma correlate with sun exposure but are not always involved in melanomagenesisS F Zerp, A van Elsas, L T Peltenburg, et al.
The Journal of Investigative Dermatology|November 1, 1994
ras oncogene activation does not induce sensitivity to natural killer cell-mediated lysis in human melanomaA van Elsas, E van Deursen, R Wielders, et al.
Melanoma Research|August 1, 1997
UV-induced N-ras mutations are T-cell targets in human melanomaA van Elsas, C Scheibenbogen, C van der Minne, et al.
Cancer Research|February 1, 1997
Activated N-ras contributes to the chemoresistance of human melanoma in severe combined immunodeficiency (SCID) mice by blocking apoptosisB Jansen, H Schlagbauer-Wadl, H G Eichler, et al.
Systems Biology|September 22, 2006
Systems biology for battling rheumatoid arthritis: application of the Entelos PhysioLab platformJ A C Rullmann, H Struemper, N A Defranoux, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 1, 1995
Analysis of N-ras mutations in human cutaneous melanoma: tumor heterogeneity detected by polymerase chain reaction/single-stranded conformation polymorphism analysisA van Elsas, S Zerp, S van der Flier, et al.
International Journal of Cancer|September 17, 1996
N-ras oncogene expression changes the growth characteristics of human melanoma in two independent SCID-hu mouse modelsB Jansen, S A Inoue, H Wadl, et al.
Pageof 2